Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infection

1 Jan 2024

Abstract excerpt

Mutagenic antiviral drugs have shown promise against multiple viruses, but concerns have been raised about whether their use might promote the emergence of new and harmful viral variants. Recently, genetic signatures associated with molnupiravir use have been identified in the global SARS-COV-2 population. Here, we examine the consequences of using favipiravir and molnupiravir to treat SARS-CoV-2 infection in a...

Topics

Join the communities discussing this publication.

CRISPR and Genetic Engineering
Plant Virus Research Studies
SARS-CoV-2 and COVID-19 Research

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 38486802
DOI: 10.1093/ve/veae001

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 1 Sept 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

0

discussions

0

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infectionPMID 38486802Read ↗

Genetic consequences of effective and suboptimal dosing with mutagenic drugs in a hamster model of SARS-CoV-2 infectionSemantic proximity Read ↗

Molnupiravir Does Not Induce Mutagenesis in Host Lung Cells during SARS-CoV-2 TreatmentSemantic proximity Read ↗

Within-host virus evolution during the extended treatment of RSV infection with mutagenic drugsSemantic proximity Read ↗

Molnupiravir Inhibits Replication of the Emerging SARS-CoV-2 Variants of Concern in a Hamster Infection Model.Semantic proximity Read ↗

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomesSemantic proximity Read ↗

A molnupiravir-associated mutational signature in global SARS-CoV-2 genomes.Semantic proximity Read ↗

SARS-CoV-2 Error Catastrophe Under Molnupiravir: Mutagenic Enhancement Enables Viral Persistence with Impaired Fitness.Semantic proximity Read ↗

The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19Semantic proximity Read ↗

Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster modelSemantic proximity Read ↗

Genome wide screen of RNAi molecules against SARS-CoV-2 creates a broadly potent prophylaxisSemantic proximity Read ↗

Molnupiravir (MK-4482) is efficacious against Omicron and other SARS-CoV-2 variants in the Syrian hamster COVID-19 modelSemantic proximity Read ↗

Determining the Mutation Bias of Favipiravir in Influenza Using Next-generation SequencingSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.